Preclinical Imaging Market Report 2026

The preclinical imaging market size has grown strongly in recent years. It will grow from $3.69 billion in 2025 to $3.93 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to increasing use of animal models in biomedical research, expansion of oncology and neurology research, rising adoption of non-invasive imaging techniques, growth in preclinical drug testing activities, availability of advanced imaging reagents.

The preclinical imaging market size is expected to see strong growth in the next few years. It will grow to $5.18 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to increasing demand for real-time disease visualization, rising investments in translational research, expansion of precision medicine studies, growing use of ai-assisted image analysis, increasing deployment of advanced contrast agents. Major trends in the forecast period include increasing adoption of multi-modal imaging platforms, rising use of high-resolution imaging systems, growing integration of imaging with data analytics, expansion of longitudinal disease monitoring studies, enhanced focus on translational imaging accuracy.

The growing burden of chronic diseases is expected to drive the growth of the preclinical imaging market in the coming years. Chronic diseases are long-term health conditions that persist for extended periods, typically lasting three months or longer, and often require continuous medical management while significantly affecting quality of life. Preclinical imaging tools are used to identify and study chronic diseases by visualizing structures such as bones and lung function. These technologies also support research by enabling visualization of disease progression and improving overall understanding of chronic conditions. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international public health agency, non-communicable diseases account for 75% of all deaths globally. Therefore, the rising prevalence of chronic diseases is contributing to the growth of the preclinical imaging market.

Major companies operating in the preclinical imaging market are increasingly focused on launching next-generation imaging systems to strengthen their competitive position. Next-generation imaging systems refer to advanced technologies that extend beyond existing capabilities by incorporating innovative and cutting-edge features. For instance, in September 2023, Revvity Inc., a US-based biotechnology company, introduced next-generation imaging systems designed to support innovation across a wide range of preclinical research applications. These launches included the IVIS Spectrum 2 and IVIS SpectrumCT 2 imaging systems, the Quantum GX3 microCT imaging solution, and a system that integrates 2D optical imaging with full 3D imaging capabilities. These systems offer enhanced image-based performance and are designed to improve workflow efficiency.

In February 2024, Bruker Corporation, a US-based medical device company, acquired Spectral Instruments Imaging for $37.5 million. This acquisition underscores Bruker’s commitment to advancing scientific research and strengthening its technological capabilities within the life sciences sector. Spectral Instruments Imaging is a US-based manufacturer specializing in preclinical optical imaging systems for bioluminescent, fluorescent, and X-ray imaging.

Major companies operating in the preclinical imaging market are Thermo Fisher Scientific Inc, FUJIFILM Visualsonics Inc, Agilent Technologies Inc, PerkinElmer Inc, Bruker Corporation, Miltenyi Biotech, Sofie Biosciences Inc, Ion Beam Applications SA, Piramal Enterprises Ltd, LI COR Biosciences Inc, Aspect Imaging Ltd, Capintec Inc, Spectral Instruments Inc, Mediso Ltd, MR Solutions Ltd, Biospace Lab SA, Scintica Instrumentation Inc, Trifoil Imaging, Bioscan Inc, Inviscan SAS, Kubtec X Ray, MILabs BV, SCANCO Medical AG, Fujifilm Holdings Corporation.

North America was the largest region in the preclinical imaging market in 2025. The regions covered in the preclinical imaging market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the preclinical imaging market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the preclinical imaging market by increasing costs of imported imaging scanners, detectors, contrast agents, electronic components, and precision optics used in MRI, PET, CT, and optical imaging systems. Research institutions in North America and Europe are most affected due to reliance on imported high-end imaging equipment, while Asia-Pacific faces higher costs for manufacturing and exporting imaging systems. These tariffs are increasing capital expenditure and delaying equipment upgrades. However, they are also driving domestic manufacturing initiatives, regional technology collaborations, and innovation in cost-efficient imaging solutions.

The preclinical imaging market research report is one of a series of new reports that provides preclinical imaging market statistics, including preclinical imaging industry global market size, regional shares, competitors with a preclinical imaging market share, detailed preclinical imaging market segments, market trends and opportunities, and any further data you may need to thrive in the preclinical imaging industry. This preclinical imaging market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Preclinical imaging involves the use of imaging techniques to visualize and analyze biological processes in animal models prior to their application in human clinical trials. These techniques enable researchers to monitor disease progression, assess the safety and effectiveness of potential therapeutics, and gain a deeper understanding of the biological mechanisms that drive diseases.

The primary modalities used in preclinical imaging include optical imaging systems, preclinical nuclear imaging systems, micro-magnetic resonance imaging systems, micro-ultrasound systems, micro-computed tomography systems, preclinical photoacoustic imaging systems, and preclinical magnetic particle imaging (MPI) systems. Optical imaging systems encompass a variety of technologies that use light to visualize and capture images of biological tissues, cells, or molecules. In the preclinical stage, optical imaging systems are used for research purposes, disease diagnosis, monitoring tumor angiogenesis, and tracking tissue blood oxygenation in animal models. These systems incorporate different reagents such as preclinical optical imaging reagents, preclinical nuclear imaging reagents, preclinical MRI contrast agents, preclinical ultrasound contrast agents, and preclinical CT contrast agents. The key end users of preclinical imaging technologies include hospitals, diagnostic centers, and others.

The preclinical imaging market includes of revenues earned by entities by providing preclinical imaging services such as magnetic resonance imaging, positron emission tomography, computed tomography, and optical imaging services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.